16 July, 2024Asceneuron secures $100 million Series C financing to advance ground breaking therapeutics in neurodegenerative diseases
12 June, 2024NodThera’s NLRP3 inhibitor NT-0796 meets primary endpoint of inflammation reversal in Phase Ib/IIa Trial in obese subjects with cardiovascular risk
7 March, 2024NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s disease phase Ib/IIa trial
6 March, 2024Asceneuron expands scientific Advisory Board with world leading experts in neurodegenerative diseases